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Abstract: Since human T-lymphotropic virus type 1 (HTLV-1)-associated diseases are 
associated with a high HTLV-1 load, reducing this load may treat or prevent disease. 
However, despite in vitro evidence that certain nucleoside/nucleotide analogue reverse 
transcriptase inhibitors (NRTIs) are active against HTLV-1, in vivo results have been 
disappointing. We therefore assayed the sensitivity of HTLV-1 primary isolates to a panel 
of RT inhibitors. HTLV-1 primary isolates were obtained, pre- and post- NRTI treatment, 
from patients with HTLV-1-associated myelopathy. Sensitivity to azidothymidine (AZT), 
lamivudine (3TC), tenofovir (TDF) and three phosphonated carbocyclic 2’-oxa-3’aza 
nucleosides (PCOANs) was assessed in a RT inhibitor assay. With the exception of 3TC, 
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HTLV RT from primary isolates was less sensitive to all tested inhibitors than HTLV-1 RT 
from MT-2 cells. HTLV-1 RT from primary isolates and from chronically infected, 
transformed MT-2 cells was insensitive to 3TC. Sensitivity of primary isolates to RT 
inhibitors was not reduced following up to 12 months of patient treatment with AZT plus 
3TC. The sensitivity of HTLV-1 primary isolates to NRTIs differs from that of cell lines 
and may vary among patients. Failure of NRTIs to reduce HTLV-1 viral load in vivo was 
not due to the development of phenotypic NRTI resistance. AZT and the three PCOANs 
assayed all consistently inhibited primary isolate HTLV-1 RT. 
Keywords:  Human T-cell Lymphotropic Virus type 1; primary isolates; reverse 
transcriptase; drug sensitivity; azidothymidine; lamivudine; tenofovir; phosphonated 
carbocyclic 2’-oxa-3’aza nucleosides 
 
1. Introduction 
Human T-lymphotropic virus type 1 (HTLV-1) is the causative agent of HTLV-1-associated 
myelopathy (HAM) [1]. This chronic debilitating disease is characterized by progressive spastic 
paraparesis, urinary, bowel and sexual dysfunction, and pain. HAM is reported to occur in 0.25% of 
HTLV-1 carriers in Japan [2] and is 10-fold higher among HTLV-1 carriers elsewhere [3]. Compared 
to HTLV-1 infected asymptomatic carriers, patients with HAM have ten-fold higher HTLV-1 proviral 
load [4] and this has been reported to predate clinical disease [5]. 
1.1. In vitro RT Inhibition 
Like the human immunodeficiency viruses (HIV-1 and HIV-2), HTLV-1 encodes reverse 
transcriptase (RT), integrase and protease enzymes that are potential therapeutic targets. In vitro 
studies have shown that the thymidine analogue RT inhibitor azidothymidine (AZT) prevented   
HTLV-1 infection [6]. In contrast, the inability of nucleoside RT inhibitor lamivudine (3TC) to inhibit 
HTLV-1 cell-to-cell transmission [7] has been ascribed to a “natural resistance” of the HTLV-1 RT to 
3TC [8,9]. Mutations at codons 151 and 184, which have been well characterized in HIV-1 drug 
resistance, have not been implicated in HTLV resistance [8]. Whilst a V-I polymorphism at codon 118 
has been found [9] it is noted that other retroviruses also exhibit natural resistance to 3TC. In addition, 
pre-activated triphosphorylated AZT inhibited HTLV-1 RT in vitro [8,10] at much lower 
concentrations than pre-activated 3TC using various cell-free RT assays [8,11]. The adenine 
nucleotide analogue, 9-(R)-[2-(phosphonomethoxy)propyl] adenine (tenofovir disoproxil fumarate, 
TDF) prevents HTLV-1 transmission in vitro and inhibits the enzymatic activity of HTLV-1 RT 
extracted from the chronically HTLV-1 infected MT-2 cell line at lower concentrations than AZT [12]. 
A new class of phosphonated nucleotide analogues, the carbocyclic 2’-oxa-3’-aza-nucleosides 
(PCOANs) are endowed with a phosphate group heavily attached to the acyclic nucleoside moiety, and 
have recently been shown to inhibit HTLV-1 RT activity and to prevent HTLV-1 transmission   
in vitro [10,13].  Viruses 2011, 3                  
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1.2. In vivo RT Inhibition 
AZT has been shown to protect rabbits from challenge with HTLV-1 infection [14], while the 
cytosine analogue 3TC was reported to reduce HTLV-1 viral load in a small open study of patients 
with HAM [15]. Between 1999 and 2002, sixteen patients with HAM participated in a randomized, 
double blind, placebo controlled study of AZT plus 3TC, the Bridge Study. After six months, as per 
study design, all patients continued with open-label AZT and 3TC. Thus, eight patients took placebo 
for six months followed by the active compounds for six months, and eight patients took AZT and 3TC 
for twelve months. Peripheral blood mononuclear cells (PBMCs) were viably preserved at four to eight 
week intervals. No significant change in HTLV-1 viral load was found up to 48 weeks of therapy with 
this combination, nor was there any improvement in immunological or clinical parameters [16].  
In vitro data had indicated that tenofovir, which has an established safety profile, inhibits HTLV-1 
RT better than other licensed RT inhibitors [17]. Thus, six patients attending the HTLV clinic were 
treated, after informed consent, off-license with 245 mg tenofovir daily for a mean of 8.7 (± 2.3) 
months. As presented below, no effect on HTLV-1 viral load was seen during treatment with tenofovir. 
Therefore, in addition to testing for phenotypic resistance to AZT and 3TC, the primary isolates from 
patients in the Bridge Study were also examined for phenotypic evidence of susceptibility to tenofovir 
and the three novel RT inhibitors. 
Here we present data on the ex vivo inhibition of HTLV-1 RT isolates from patients who 
participated in the Bridge study pre and post therapy. We demonstrate that the NRTI sensitivity of 
HTLV-1 RT derived from cell lines differs from that of primary isolates, and show differences in drug 
susceptibility between primary isolates. 
2. Results and Discussion 
2.1. RT Activity in Isolates from both HAM Patient PBMC Cultures and from the HTLV-1 Chronically 
Infected MT-2 Cell Line 
To test the in vitro inhibitory activity of different compounds on HTLV-1 RT from patient isolates, 
the optimal amount of RT needed to generate cDNA from a known RNA template was first assessed in 
centrifugation-enriched isolates from patient PBMC culture and, for comparison, from MT-2 cell 
cultures. Isolates were prepared from PBMC cultures of all of the patients under study collected before 
and after 48 weeks of therapy with AZT plus 3TC except for patient TBJ, due to insufficient material. 
The amount of HTLV-1 p19 in the enriched isolates was quantified as a surrogate measure of the 
amount of RT. Serial dilutions of resuspended isolates, corresponding to 5 to 30 pg of p19, were added 
to the assay mixture in order to determine the amount of p19-equivalent HTLV-1 RT to be used in the 
assay. The amount of amplified product plateaued with the addition of isolate preparations 
corresponding to 20–30 pg of p19 (Figure 1). These results indicated that the utilized assay was 
sensitive enough to measure RT activity in PBMC cultures from HTLV-1 infected patients and that 
isolates from HAM patient PBMC cultures, before and after therapy, and from MT-2 cells plateaued 
for RT activity at similar p19-equivalent concentrations. Based on these results, supernatants 
containing the equivalent of 24 pg of p19 were used in all the subsequent inhibitory assays.  
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Figure 1. RT activity in human T-lymphotropic virus type 1 (HTLV-1) isolates from 
peripheral blood mononuclear cell (PBMC) cultures of HTLV-1-associated myelopathy 
(HAM) patients. Centrifuge-enriched isolates from PBMC cultures of 5 patients with HAM 
(TAY, TAR, TAU, TBI, TAQ), before (T0) and after (T48) therapy with 3TC plus AZT, or 
from MT-2 cells, were assayed for p19. Serial dilutions of p19-equivalent isolates were 
added to the RT assay and amplified products of the template were visualized on a 2% 
agarose gel and quantitated by densitometry, as a measure of RT activity.  
 
2.2. Sensitivity of Patient HTLV-1 Isolates to RT Inhibitors 
The concentration of AZT, 3TC, TDF and of PCOAN1, PCOAN2, PCOAN3 required to inhibit RT 
activity in primary isolates prior to and after any antiretroviral therapy was determined. The 
concentrations used are shown in Table 1. HTLV-1 RT from these PBMC culture derived primary 
isolates was inhibited by AZT (4–8 nM), which was ten-times more than the concentration required to 
inhibit RT from MT-2 cells (Table 2). In samples from five out of six patients and from MT-2 cells the 
inhibitory concentration of 3TC was >10
3 nM but in one patient (TBJ) the inhibitory concentration of 
3TC was 400 nM. HTLV-1 RT from MT-2 cells was susceptible to TDF at 0.4 nM but 10–1000 nM of 
this compound were required to inhibit RT from the primary isolates. The three unlicensed compounds 
all inhibited MT-2 HTLV-1 RT at 0.8 nM and also inhibited HTLV-1 RT from the primary isolates at 
2–10 nM, with PCOAN1 being the most potent. No change in the inhibitory concentration of any RT 
inhibitor was seen in the primary isolates obtained from patients after 6 to 12 months therapy with 
AZT plus 3TC.  Viruses 2011, 3                  
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Table 1. Compounds and concentrations. 
Compound  Concentrations in nM 
Azidothymidine 10 8 6 4 2 1 
Lamivudine 1000 800 600 400 200 100 
Tenofovir df  1000 100 10  1  0.1   
PCOAN1  10 8 6 4 2 1 
PCOAN2  10 8 6 4 2 1 
PCOAN3  10 8 6 4 2 1 
2.3. Virus Release in Cultures of PBMCs from Patients with HAM 
The supernatants utilized for obtaining centrifugation-enriched isolates to assay, were also 
evaluated for viral particle production by measuring released p19. Figure 2 shows that MT-2 cells 
produced more p19 (40 pg/µL) than did cultures of PBMCs from HAM patients (5–20 pg/µL). 
However the amount of p19 in supernatants from PHA stimulated PBMCs from patients with HAM 
was similar before and after 48 weeks of antiretroviral treatment. 
Figure 2. p19 release in culture supernatants from PBMCs of HAM patients before and 
after therapy. The p19 concentration in supernatants from PBMC cultures of 5 patients 
with HAM (TAY, TAR, TAU, TBI, TAQ), before (T0) and after (T48) therapy with 3TC 
plus AZT, was evaluated by ELISA. Values are expressed as the mean of quadruplicate 
samples ± standard deviation. Production of p19 (black column) in the supernatant of 
chronically infected cells MT-2 was used as a positive control. 
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Table 2. In vitro human T-lymphotropic virus type 1 (HTLV-1) RT inhibitory concentrations (nM). 
Patient 
Time 
Point 
Duration of 
AZT/3TC 
HTLV-1 DNA 
Copies/ 100 
PBMCs 
AZT 3TC TDF  PCOANs 
Mutations Detected by HTLV-1 Proviral-DNA pol Gene 
Sequence Analysis Compared with Reference Sequence—
Accession Number NC_001436.1 
            1 2 3  
TAY                  
Week 0    1.0  6  >10
3 10  2 6 4 None  detected   
Week 48  24 weeks  4.8  6  >10
3 10  2 6 4 None  detected   
TAR                  
Week 0     4.3  6  >10
3 10
2  4 10  6 None  detected 
Week 48  48 weeks  0.6  6  >10
3 10
2  4  10  6  12 nt duplication at position 3551 
TAU                  
Week 0    2.0  6  >10
3 10  4 10  8 None  detected 
Week 48  24 weeks  1.0  6  >10
3 10  4 8 8 None  detected 
TBI                  
Week 0    3.4  6  >10
3 10  6 10  6 None  detected 
Week 48  48 weeks  17.7  6  >10
3 10  8 10  6 None  detected 
TBJ                  
Week 0     6.3  4  4
*10
2 10
2  8  10  10  2 nt insertion at position 2935 
Week 48  48 weeks  8.1  Insufficient material 
TAQ                  
Week 0    2.6  8  >10
3 10
3  8  10  8  102 nt deletion at position 4031 
Week 48  24 weeks  1.3  8  >10
3 10
3  8  10  8  75 nt deletion at position 4102 
MT-2     0.4  >10
3 0.4 
0.
8 
0.
8 
0.
8 
None detected 
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2.4. Proviral Load and pol Sequence 
In vivo HTLV-1 DNA loads and the duration of exposure to nucleoside analogues are presented in 
Table 2. As previously reported, no significant change in HTLV-1 proviral load was seen in vivo after 
24–48 weeks of therapy with AZT plus 3TC [16]. In our samples the median viral load was 3.0 copies 
per 100 PBMCs before therapy, and 3.05 copies per 100 PBMCs after therapy. To determine whether 
the lack of reduction in proviral load was due to mutations in the HTLV-1 reverse transcriptase, 
proviral pol was sequenced at baseline and at the conclusion of therapy. In three patients the consensus 
sequence was wild type at both time points. Conversely, duplications, insertions or deletions were 
observed in the other three patients. However, no relationship was observed between individual 
proviral load variations and detection of mutations in patients. Thus, apparently the lack of reduction 
in proviral load was not due to the outgrowth of mutated viruses.  
2.5. In vivo Exposure to Tenofovir  
TDF was well tolerated with no reported side effects. Whilst some patients exhibited a deterioration 
during therapy those patients who received therapy for longest had measurable improvement in pain 
and/or gait (Tables 3 and 4). Total lymphocyte count increased during treatment with TDF due to 
increases in both CD4+ and CD8+ lymphocytes. However, no significant change in HTLV-1 viral load 
was seen during up to 16 months therapy with TDF (Figure 3). The median baseline HTLV viral load 
was 15.2 HTLV-1 DNA copies /100 PBMCs compared to 19.6 HTLV-1 DNA copies /100 PBMCs 
after therapy with TDF. 
Figure 3. In vivo HTLV-1 viral load (HTLV DNA copies /100 PBMCs) during treatment 
with tenofovir. 
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Table 3. Clinical, virological and immunological outcomes of patients with HAM receiving tenofovir (TDF)  at baseline and at end of 
treatment. 
  
 
TDF Started  TDF Stopped 
Mean Difference (SD) P 
(%, ±SD)  (%, ±SD) 
Timed walk  Mean  14.2 (±3.5)  16.1 (±2.6)  +1.9 (±2.7)  0.4 
   Median  16.7  15.8       
Visual analogue pain score  Mean  4.1 (±1.7)  4.7 (±2)  +0.6 (±1.3)  0.3 
   Median  7  7.5       
HTLV-I proviral load (copies/100 PBMCs)  Mean  39.8 (±14)  38.9 (±13)  −0.9 (±12.7)  0.9 
   Median  15.2  19.6       
Lymphocyte count (10
9/L)  Mean  2320 (±1070)  2882 (±1395)  +562 (±575)  0.07 
   Median  1800  2710       
CD4+ T lymphocyte (10
9/L)  Mean  962 (±567)  1218 (±640)  +256 (±582)  0.35 
   Median  840  1390       
CD8+ T lymphocyte (10
9/L)  Mean  620 (±399)  774 (±529)  +154 (±546)  0.9 
   Median  530  560       
Table 4. Percent change in clinical and laboratory parameters when tenofovir treatment was stopped compared to baseline values. 
Patient 
Duration of 
Treatment 
(Months) 
TW (%) 
VAS 
(%) 
VL (%) 
VL Log 
Change 
Total 
Lymphocyte 
Count (%) 
CD4+ (%)  CD8+ (%) 
I  2.08 wc  Nd  −1.5  −0.007 15  nd  nd 
II  2.55  −4.7 0  312.3  −0.23  −16.7  −60.7  −52.8 
III  8.33 2.6  36.4  −16.1 0.12  33.3  36.4  15.2 
IV  9.49 11.1  25  11.9  0.62  8.1  18.6  −12.5 
V  12.26  −23.1 0  −40.6  −0.08 0 414.8  325.8 
VI  16.56  −13.3  −14.3 28.4  0.05  43.8  8.3  5.4 
TW = timed walk, VAS = visual analogue pain score, VL = HTLV-I viral load, wc = wheelchair, nd = not done. 
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3. Experimental Section  
3.1. Materials and Patients  
In addition to the published ‘Bridge Study’, blood samples were collect during a study of the 
pathogenesis and treatment of HTLV-1 between April 2004 and May 2005, from five patients with 
HAM and one diagnosed with HTLV-1-associated encephalitis. The study was approved by the local 
research ethics committee. These patients had been, after informed consent and on a case-by-case 
basis, treated with TDF based on in vitro HTLV-RT data [12,17]. At the initiation of TDF treatment 
their mean age was 44.8 (± 15) and the mean duration of HAM was 8.3 (± 6.8) years. One patient was 
co-infected with HBV (HBeAg+). Four patients were female and three West African. Heterosexual 
intercourse was the most common route of HTLV-1 acquisition. Routine clinical and laboratory data 
were collected and pre and post-treatment values analyzed by T-test. 
3.2. Cell Culture and Isolate Preparation 
PBMCs from heparinized blood of patients with HAM were separated by Ficoll/Hypaque density 
gradient (Pharmacia Uppsala, Sweden) and then washed three times in phosphate buffered saline 
(PBS). To use virus isolates from patients as a source of RT for the subsequent assay, paired samples 
of PBMC at week 0 and week 48 from six patients were cultured at 0.8 × 10
6 cells/mL in RPMI plus 
15% FBS in the presence of 20 U/mL of IL-2, following a two-day stimulation with PHA. PBMCs 
from patients were maintained in culture for 3–4 weeks. PBMCs were pelleted weekly, supernatants 
harvested and fresh medium completely replenished. Aliquots of the harvested supernatants were 
utilized to detect viral particle production by p19 release, while the rest were cleared at 1,000 g and 
then ultracentrifuged at 30,000 g for 4 h at 4 °C. HTLV-1 p19 viral protein in centrifugation-enriched 
viral lysates was detected using a commercially available ELISA (see Section 3.6).  
3.3. HTLV-1 Proviral Load 
HTLV-1 proviral load in the patients treated with TDF was measured by quantitative real-time PCR 
as previously reported [18]. Samples were available at baseline, after 2 weeks and at 4 weekly 
intervals out to a maximum of 32 weeks. 
3.4. In vitro Assayed Compounds 
Three licensed reverse transcriptase inhibitors (AZT, 3TC and TDF) and three experimental 
compounds prototype PCOANs referred to as, PCOAN1, PCOAN2 and PCOAN3 were used. The 
acyclic phosphonate TDF was kindly provided by Dr. Jan Balzarini (Rega Institute for Medical 
Research, Leuven, Belgium) while AZT and 3TC were provided by Wellcome Research Laboratories 
(Beckenham, England, UK). The PCOANs are a family of newly synthesized compounds which 
belong to a group of cyclic nucleoside phosphonates, with the furanose ring replaced by an   
N,O-heterocyclic ring [19,20]. PCOANs were dissolved in DMSO and maintained at stock 
concentrations of 200 mM at −20 °C. TDF, AZT and 3TC were dissolved in culture medium without 
serum and maintained at stock concentrations of 100 mM at −20 °C.  Viruses 2011, 3                  
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3.5. HTLV-1-RT Activity Assay 
To test the sensitivity of HTLV-1 isolates from patients to RT inhibitors we set up a novel ex vivo, 
cell-free HTLV-1-RT activity assay. This assay is a modified version of a method we have described 
and used to screen the HTLV-1-RT-inhibitory activity of antiretroviral compounds in vitro [10,12]. 
The modification essentially consists of using patient isolates, prepared as described in Section 3.2, as 
source of HTLV-1 RT in place of viral lysates from HTLV-1 chronically infected cell lines. RNA 
template to be subjected to reverse transcription into cDNA, was obtained from stably transfected cells 
ectopically expressing the herpes simplex virus type 1 glycoprotein D (gD) gene [21] and treated with 
RNase free DNase. 
Compounds to which sensitivity was assayed were activated by pre-incubating with a crude extract, 
prepared from PHA plus IL-2 stimulated PBMCs from healthy, HIV/HBV/HCV negative donors. To 
prepare the crude extract, 1 × 10
6 PBMCs, previously stimulated with PHA (2 g/mL) and IL-2   
(20 U/mL), for 72 h in RPMI plus 20% FCS, were lysed on ice in buffer (50 mM Tris-HCl pH 7.4, 1 
mM EDTA, 1 mM EGTA pH 7.4, 0.05% Triton-X, 150 mM NaCl, 0.25% sodium deoxycholate, 0.1% 
NP-40 and, freshly added, 1 mM PMSF, 15 M DTT, 5 g/mL leupeptin, 5 g/mL pepstatin, 5 g/mL 
aprotinin, 1 mM Na3VO4, 20 mM Na3F, all from Sigma), and centrifuged at 10000 g. Lysed extracts 
were incubated with different compound concentrations for 15 minutes on ice followed by 45 minutes 
at 30 °C and then a 5 minute incubation at 95 °C to inactive the mixture. As an ex vivo source of  
HTLV-1 RT, viral lysates from different HAM patient sample isolates (24 pg of p19-equivalent 
material) were used for each RT-PCR reaction. Total DNase-treated RNA (1 g) was specifically 
reverse transcribed using 0.5 M reverse primer specific for the gD gene US6  
(5’ TGTCGTCATAGTGGGCCTCCAT 3’) in a reaction mix containing 1 × RT buffer, 100 U RNase 
inhibitor, 1 mM dNTP, 10 mM DTT, (all from Promega, Madison, WI, USA) plus HTLV-1-RT 
preparations from patients in a volume of 10 L. The reactions were performed in the presence or 
absence of activated substances, for 1 h at 37 °C. After incubation at 95 °C for 5 minutes, DNA PCR 
(20 cycles) was performed using 5 L of RT reaction in a mix containing 1X Taq Gold buffer 
(Promega), 0.5 M primer pair (US6 reverse, see above, and US6 forward, 5’ 
AGACTTGTTGTAGGAGCATTCG 3’), 0.2 mM dNTP, 5 mM MgCl2, 1.25 U Taq Gold Polymerase 
(Promega). To investigate the dose–response, the assayed compounds, AZT, 3TC, TDF or PCOAN1, 
PCOAN2, PCOAN3 were added at the concentrations shown in Table 1. Amplified DNA (350 bp) was 
visualized on a 2% agarose gel containing ethidium bromide. HTLV-1 RT preparations from cultured 
MT-2 cells were used as a control.  
3.6. Detection of p19 through Antigen Capture Assay 
p19 in supernatants or enriched isolates was assayed using an HTLV-1 p19 Gag antigen capture 
enzyme-linked immunosorbent assay (ELISA) (ZeptoMetrix, Buffalo, NY, USA). Assays were 
performed according to the manufacturer’s protocols. Viruses 2011, 3                  
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3.7. Genotypic Analysis of HTLV-1 pol Gene 
Genotypic analysis of the entire pol  coding region corresponding to nucleotides 2100–5076 of 
HTLV-1 reference sequence (NC_001436.1) was performed by sequencing PCR products from DNA 
of MT-2 cells and of cultured cells from patients enrolled in the study at baseline and at week 48 (post 
AZT and 3TC therapy). Primer pairs were designed to amplify overlapping products of about 300 
nucleotides in length. 
4. Conclusions 
The sensitivity of HTLV-1 primary isolates to AZT, 3TC, TDF and three novel PCOANs has been 
determined using a novel RT inhibition assay. Using PBMCs from patients with HAM who had been 
treated for up to 48 weeks with AZT and 3TC, we have demonstrated for the first time, both the 
sensitivity of HTV-1 RT to AZT and its primary resistance to 3TC in HTLV-1 clinical isolates. 
Furthermore we have shown that prolonged in vivo treatment with AZT and 3TC was not associated 
with the development of reduced sensitivity of HTLV-1 RT to these nucleoside analogues or with 
consistent changes in the sequence of RT. Therefore, we conclude that the lack of viral, and 
consequent lack of immunological and clinical response seen in this study [16] was not due to the 
development of genotypic or phenotypic resistance. Since the proviral pol consensus sequence was 
identical to the reference sequence in 3/6 patients these results will likely be applicable to the majority 
of patients infected with HTLV-1. 
Unexpectedly, the HTLV-1 RT from patients’ PBMCs displayed considerable variability in TDF 
sensitivity and consistent sensitivity to PCOANs. In the present study, the phenotypic RT sensitivity of 
whole virus primary isolates from patients with HAM was quantitatively similar in samples from 
untreated versus RT inhibitor treated patients, and at least one order of magnitude, and in some cases a 
thousand times, less sensitive to AZT and to TDF than RT from MT-2 cells. This lack of sensitivity to 
TDF was seen prior to, and not altered by, in vivo NRTI exposure. We have not, at the moment, a clear 
explanation for the different sensitivity of isolates from patients and MT-2 associated virus to   
RT-inhibitors. However, we have previously demonstrated variable efficacy of RT inhibitors against 
HTLV-1 RT from different transformed cell lines. For example, the concentration of PCOAN2 needed 
to inhibit RT activity from C5/MJ and MT-2 cell supernatants was 10–100 times less than that 
required to inhibit RT from C91/PL cells. Similarly, the concentration of TDF needed to inhibit RT 
from MT-2 cell supernatants was 10–100 times less than that required to inhibit RT from C91/PL and 
C5/MJ cells. Conversely, RT from HUT 102 supernatants was resistant to most of the RT inhibitors 
used [13]. Whereas, a study in which RT produced only from an infectious HTLV-1 molecular clone 
derived from CS-1 cells (HTLV-1 transformed B cell line) was utilized, concluded that HTLV-1 was 
highly sensitive to TDF [17]. Thus, phenotypic sensitivity of HTLV-1 RT to inhibitors seems a 
phenomenon much more variable than expected by genotypic relatively low variability of the virus. 
Further study is needed on this aspect.  
While the data from this study do not suggest that a combination of AZT with TDF might inhibit 
HTLV-1 RT in some patients, this possibility remains. We therefore promote pre-treatment phenotypic 
sensitivity testing to avoid unnecessary exposure to these therapies. Conversely, each of the PCOANs 
assayed had an RT inhibitory concentration similar to that of AZT suggesting that these compounds Viruses 2011, 3                  
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should be considered in future studies. We have recently demonstrated that these new RT inhibitors, 
PCOANs, are able to inhibit HTLV-1 cell-to cell transmission in vitro using MT-2 and HTLV-1 donor 
cells as a source of HTLV-1 as effectively as TDF and AZT [13]. 
The presence of defective HTLV-1 proviruses in clinical samples is well known [22] and our 
findings here, together with recent data on the number and size of clonally expanded HTLV-1 infected 
cells in vivo [23], suggest that the consensus sequencing has, in some patients, amplified DNA from 
dominant clones that may not be replication competent. However, the persistent phenotypic sensitivity 
of RT from HTLV-1 isolates to AZT, including those cases in which mutated/deleted forms of proviral 
pol were detected, suggests that the lack of virological effect in the dual therapy clinical trial was not 
due to the emergence of mutations in RT during therapy. This finding supports the hypothesis that RT 
only partially explains HTLV-1 viral load maintenance and spread within patients with HAM while 
mitosis plays a major role in maintaining HTLV-1 viral burden. It is less likely that viral load was 
maintained by HTLV-1 infection in drug sanctuary sites with migration of infected lymphocytes into 
the peripheral blood.  
Overall, patients treated with TDF showed no clinical improvement. The apparent association 
between longer duration of TDF therapy and reduced pain and 10m timed walk most likely reflects a 
bias to continue therapy due to perceived benefit. The CD4+ and CD8+ T lymphocyte count rose 
significantly from baseline. In HIV infection a rise in CD+ T lymphocyte count is associated with a 
decreased HIV RNA viral load in patients treated with TDF and other antiretroviral therapies. We 
could not find previous reports of a change in lymphocyte counts in HIV or HTLV-1 non-infected 
patients treated with antiretrovirals. In HTLV-1 infected patients AZT did not cause a significant rise 
of lymphocyte counts. In our earlier study of patients with HAM receiving dual-therapy with AZT and 
3TC, the CD4+ T lymphocyte counts rose, but the total lymphocyte count and the CD8+ T lymphocyte 
count fell. In the same study total lymphocyte and subset counts increased in the placebo group at 
week 24 but by much less than seen in patients treated with TDF. We hypothesize that, in addition to 
the antiretroviral effect, TDF therapy is associated with a virus independent increase in lymphocyte 
and T cell subset counts. 
Is there any role for HTLV-1 RT inhibitors in clinical practice? Treatment of adult T-cell 
leukaemia/lymphoma with AZT together with interferon-currently induces remission in about 70% 
of patients. However, there is no evidence that the available RT inhibitors, given as monotherapy or in 
combination with other RT inhibitors, reduce HTLV viral load. Recently, AZT in combination with a 
histone deacetylase inhibitor significantly and persistently reduced STLV-1 viral load in naturally 
infected baboons over three months of treatment [24] and reproduction of this effect in HTLV-1 
infection in vivo is urgently required. 
If sustained reduction in HTLV-1 viral load in patients with, or at risk of, HAM requires long term 
combination therapy that includes an RT inhibitor, less toxic alternatives to AZT will be desirable. 
TDF, which is better tolerated than AZT, would be a suitable candidate based on data using MT-2 cells 
as donor cells or as a source of RT. However, our data suggest that TDF might not be as effective as 
AZT in vivo, due to its reduced sensitivity in treating naïve HTLV-1 primary isolates. Thus, alternative 
HTLV-1 inhibitors should be tested.  
Since HTLV-1 is a highly cell-associated virus, RT inhibitors might be useful in clinical trials when 
used in combination with compounds such as cell signaling modulators [25]. Therefore, predicting the Viruses 2011, 3                  
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sensitivity of HTLV-1 isolates from patients to different RT inhibitors using our ex vivo cell-free assay 
may be particularly useful in preclinical studies for future clinical trials.  
While HTLV-1 RT inhibitors are not routinely used clinically to reduce the risk of transmission 
following occupational exposure or following delivery by an HTLV-1 infected mother, they remain the 
only potential therapies for pre- or post- exposure prophylaxis. The data presented here suggest that 
AZT rather than TDF (unless sensitivity is known) would be the preferred therapeutic agent following 
high-risk exposure. The lack of efficacy in the six patients studied, in conjunction with the ex vivo data 
from an additional six patients who were not exposed to TDF, suggests that reduced sensitivity may be 
common but this needs to be confirmed with more HTLV-1 primary isolates. These data suggest a 
general lack of RT efficacy when used alone as an anti-HTLV therapy in patients with HAM, justify 
further studies of novel drug combinations and/or PCOANs to treat and prevent HTLV-1 infection, 
and provide a tool to test HTLV-1 RT susceptibility to trial drugs ex vivo.  
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